Oral Vitamin E Supplementation for the Prevention of Anemia in Premature Infants: A Controlled Trial

Serum vitamin E levels are reduced in newborn infants. It has been reported that this deficiency is responsible, in part, for the development of anemia in premature infants during the first 6 weeks of life. The efficacy of vitamin E supplementation for the prevention of anemia in premature infants has been studied in a randomized, controlled, and blinded trial. Premature infants whose birth weights were less than 1,500 g were given, by gavage, 25 IU of dl-α-tocopherol or a similar volume of the drug vehicle. Treatment was continued for the first 6 weeks of life. A total of 178 infants were studied. Vitamin E levels were significantly higher in a supplemented group by day 3 and for the remainder of the 6-week period. At 6 weeks of age, there was no significant difference between the supplemented and unsupplemented groups in hemoglobin concentration, reticulocyte and platelet counts, or erythrocyte morphology. It is concluded that there is no evidence to support a policy of administering vitamin E to premature infants to prevent the anemia of prematurity.

Download Full-text

Can Vitamin E Deficiency Occur in an Infant Receiving Total Parenteral Nutrition?

PEDIATRICS ◽

10.1542/peds.59.5.789 ◽

1977 ◽

Vol 59 (5) ◽

pp. 789-790

Author(s):

A. Myron Johnson ◽

Mary Ann Williams Morris

Keyword(s):

Vitamin E ◽

Parenteral Nutrition ◽

Total Parenteral Nutrition ◽

Premature Infants ◽

Newborn Infants ◽

Vitamin E Deficiency ◽

Gastrointestinal Obstruction ◽

Lipid Supplementation ◽

Upper Gastrointestinal ◽

Vitamin E Supplementation

Reports in the July 1975 issue of Pediatrics of total parenteral nutrition (TPN) in newborn infants, with and without lipid supplementation,1,2 have prompted a brief report of our experience with a small premature infant given TPN because of upper gastrointestinal obstruction and postoperative intolerance of enteral nutrition. Although cause-and-effect relationships are far from clear, this infant's course raises a question about the adequacy of vitamin E supplementation for premature infants receiving TPN. Case Report. F.I. (No. 31-10-62) was the first born in a pair of dizygotic black twins, weighed 1,370 gm, and was the product of a 30-week gestation terminated by spontaneous rupture of membranes.

Download Full-text

DEFICIENCY OF NEUTROPHIL PHAGOCYTOSIS IN PREMATURE INFANTS: EFFECT OF VITAMIN E SUPPLEMENTATION

Acta Paediatrica ◽

10.1111/j.1651-2227.1983.tb09764.x ◽

1983 ◽

Vol 72 (4) ◽

pp. 521-524 ◽

Cited By ~ 24

Author(s):

G. CHIRICO ◽

M. MARCONI ◽

A. COLOMBO ◽

A. CHIARA ◽

G. RONDINI ◽

...

Keyword(s):

Vitamin E ◽

Premature Infants ◽

Vitamin E Supplementation

Download Full-text

Comparative Study on Vit. E & Mefenamic acid vs Mefenamic acid alone on mean reduction in pain in Primary Dysmenorrhea

10.53350/pjmhs2115123195 ◽

2021 ◽

Vol 15 (12) ◽

pp. 3195-3197

Author(s):

Fariha Sadiqa ◽

Mufakhara Fatimah ◽

Abdul Mudabbir Rehan ◽

Sidra Mushtaq ◽

Asia Firdous ◽

...

Keyword(s):

Vitamin E ◽

Mefenamic Acid ◽

Controlled Trial ◽

Acid Group ◽

P Value ◽

Primary Dysmenorrhea ◽

High Concentration ◽

Randomized Controlled ◽

Significant Difference ◽

Menstrual Fluid

Background: Pelvic pain around the time of mensturation without any identifiable pathologic lesion present from menarche is called primary dysmenorrhea. The pain is believed to be related to prostaglandin (PG). Women with dysmenorrhoea have a relatively high concentration of PGF 2 alpha in menstrual fluid and suppression of PG synthesis has become the main treatment. Aim: To compare mean reduction in pain in patients presenting with primary dysmenorrhea given vitamin E & Mefenamic acid versus Mefenamic acid alone. Results: It was a randomized controlled trial which was conducted in Department of Obstetrics & Gynecology, THQ Raiwind Hospital, Lahore for 6 months duration w.e.f 01/02/2017 to 31/07/2017. In this study, 18(36%) in Vitamin-E group and 21(42%) in Mefenamic acid group were between 15-20 years while 32(64%) in Vitamin-E group and 29(58%) in Mefenamic acid group were between 21-25 years, mean±sd was calculated as 20.86±2.92 and 20.66±2.86 years respectively, mean dysmenorrheal pain at baseline was recorded as 50.06±10.27 in Vitamin-E group and 50.14±10.28 in Mefenamic acid group, p value < 0.754, showing that both groups are insignificant, mean dysmenorrheal pain after treatment was recorded as 20.50±10.04 in Vitamin-E group and 30.22±10.28 in Mefenamic acid group, p value was < 0.002 showing significant difference between the two group, comparison of mean reduction in dysmenorrheal pain after treatment was recorded as 20.56±0.91 in Vitamin-E group and 10.92±0.75 in Mefenamic acid group, p value was < 0.000, showing significant difference. Conclusion: We concluded that there is a significant mean reduction in dysmenorrhic pain in patients given Mefenamic Acid + Vitamen E as compared to patients given Mefenamic Acid alone. Keywords: Dysmenorrhic pain, Mefenamic Acid + Vitamen E, mean reduction in dysmenorrhic pain

Download Full-text

Effects of Vitamin E Supplementation to Metabolic Markers on Diet-Induced Obesity in Mice

Folia Medica ◽

10.3897/folmed.63.e57877 ◽

2021 ◽

Vol 63 (6) ◽

pp. 895-900

Author(s):

Eka Roina Megawati ◽

Lokot Donna Lubis ◽

Febi Yanti Harahap

Keyword(s):

Body Weight ◽

Vitamin E ◽

Blood Sugar ◽

Adiponectin Level ◽

Metabolic Markers ◽

Diet Induced Obesity ◽

Cholesterol Levels ◽

Significant Difference ◽

Obesity In Mice ◽

Vitamin E Supplementation

Introduction: Obesity creates health problems by increasing the risks of chronic diseases such as type 2 diabetes and cardiovascular disorders. Obesity leads to insulin resistance, higher blood glucose and cholesterol levels. Adipose tissues synthesize adiponectin which acts as anti-inflammatory, antidiabetic, and anti-atherogenic agent. Meanwhile, vitamin E is an antioxidant that acts as an anti-inflammation. Aim: The purpose of this study was to analyze the effects of vitamin E supplementation to metabolic markers on diet-induced obesity in mice. Materials and methods: Twenty-four mice (Mus musculus, L) aged four weeks were divided into six groups which were fed different diets and given vitamin E in different dosages or methods. The period of treatment was 18 weeks. The mice body weights were measured every week; blood sugar and cholesterol levels were measured every six weeks, and the adiponectin level measurement was done at week 18. Results: A repeated measures ANOVA showed that body weight and cholesterol level within groups were not significantly different [F(15, 54)=1.417, 0.173 and F(10, 36)=1.391, 0.224 respectively]. The glucose levels were found to be significantly different [F(7.646, 27.526)=2.625, 0.030]. There was no significant difference in the adiponectin levels. Conclusions: Vitamin E supplementation could not prevent the increase of body weight, the elevation of blood sugar and cholesterol levels, and also could not increase adiponectin level.

Download Full-text

Daily vitamin E supplementation does not improve metabolic and glycemic control in type 2 diabetic patients: A double blinded randomized controlled trial (2型糖尿病患者每日添加维生素E治疗不能改善代谢与血糖控制：一项双盲随机对照试验)

Journal of Diabetes ◽

10.1111/j.1753-0407.2012.00206.x ◽

2013 ◽

Vol 5 (1) ◽

pp. 57-58 ◽

Cited By ~ 6

Author(s):

Sakineh SHAB-BIDAR ◽

Zohreh MAZLOUM ◽

Zahra MOUSAVI-SHIRAZIFARD

Keyword(s):

Randomized Controlled Trial ◽

Vitamin E ◽

Controlled Trial ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Randomized Controlled ◽

Double Blinded ◽

Type 2 Diabetic ◽

Vitamin E Supplementation

Download Full-text

Retrolental Fibroplasia and Vitamin E in the Preterm Infant—Comparison of Oral Versus Intramuscular:Oral Administration

PEDIATRICS ◽

10.1542/peds.73.2.238 ◽

1984 ◽

Vol 73 (2) ◽

pp. 238-249

Author(s):

Helen M. Hittner ◽

Michael E. Speer ◽

Arnold J. Rudolph ◽

Cindy Blifeld ◽

Prabhujeet Chadda ◽

...

Keyword(s):

Vitamin E ◽

Very Low Birth Weight ◽

Plasma Vitamin ◽

Oral Vitamin ◽

Low Birth Weight Infants ◽

Retrolental Fibroplasia ◽

Intramuscular Injections ◽

Significant Difference ◽

Plasma Vitamin E ◽

Vitamin E Supplementation

To evaluate the efficacy of four early intramuscular injections of vitamin E given in addition to continuous minimal oral vitamin E supplementation, 168 very low-birth-weight infants (≤1,500 g) have enrolled in a randomized, double-masked, clinical study. All infants received vitamin E orally, 100 mg/kg/d. In addition, on days 1, 2, 4, and 6, seventy-nine infants received vitamin E intramuscularly, 15, 10, 10, and 10 mg/kg, respectively. On the same days, 89 control infants received placebo intramuscular injections. Multivariate analysis of the 135 infants who survived ≥10 weeks showed no significant difference in the development of severe retrolental fibroplasia between these two supplementation schedules (P = .86). Plasma vitamin E levels never exceeded a mean of 3.3 mg/100 mL, and no toxicity was observed. Ultrastructural analyses of seven pairs of whole eye donations from infants receiving IM vitamin E demonstrated identical kinetics of gap junction formation between adjacent spindle cells as compared with 13 pairs of whole eye donations from control infants (P > .3). Therefore, oral vitamin E supplementation affords retinal protection against the development of severe retrolental fibroplasia when initiated on the first day of life and maintained continuously until retinal vascularization is complete.

Download Full-text

Protective Effects of Vitamin E on Chemotherapy-Induced Peripheral Neuropathy: A Meta-Analysis of Randomized Controlled Trials

10.21203/rs.2.22123/v1 ◽

2020 ◽

Author(s):

Huikai Miao ◽

Rongzhen Li ◽

Dongni Chen ◽

Jia Hu ◽

Youfang Chen ◽

...

Keyword(s):

Vitamin E ◽

Peripheral Neuropathy ◽

Randomized Controlled Trials ◽

Lower Incidence ◽

Meta Analysis ◽

Controlled Trials ◽

Modest Improvement ◽

Randomized Controlled ◽

Significant Difference ◽

Vitamin E Supplementation

Abstract Background Chemotherapy often causes chemotherapy-induced peripheral neuropathy (CIPN), but effective prevention measures are still lacking. Whether vitamin E can prevent peripheral neurotoxicity caused by chemotherapy is inconclusive. Therefore, we collected related randomized controlled trials (RCTs) and conducted a meta-analysis to examine whether vitamin E could prevent CIPN. Methods We searched PubMed, EMBASE and the Cochrane databases in November 2019 for eligible trials. Two reviewers conducted the analysis independently when studies were homogeneous enough. Results Eight RCTs, involving 555 patients, were identified. Upon pooling these RCTs, patients who received vitamin E supplementation of 600 mg/day had a significantly lower incidence of peripheral neuropathy (RR 0.31; 95% CI 0.14 to 0.65; P = 0.002) induced by chemotherapy compared with the placebo group. Vitamin E played a key role in decreasing the incidence of peripheral neuropathy in the cisplatin chemotherapy group (RR 0.28; 95% CI 0.14 to 0.54; P = 0.0001). With regard to improvements in sural amplitude, vitamin E supplementation significantly decreased patients’ sural amplitude after three rounds of chemotherapy (RR -2.66; 95% CI -5.09 to -0.24; P =0.03) in contrast with that of placebo supplementation, while no significant difference was observed when patients were treated with vitamin E after six rounds of chemotherapy. In addition, the vitamin E group had better improvement in the neurotoxicity score (RR -2.65; 95% CI -4.01to -1.29; P = 0.0001) and a lower incidence of reflexes and distal paraesthesias (RR 0.50; 95% CI 0.29 to 0.87; P = 0.01) compared to the control group. Conclusion Available data included in this meta-analysis showed that vitamin E supplementation can confer modest improvement in the prevention of CIPN. However, large-scale, well-designed RCTs are needed to confirm the exact role of vitamin E supplementation in the prevention of CIPN.

Download Full-text